This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Keleti, J. Articles by Tsokos, M. Search for Related Content PubMed PubMed Citation Articles by Keleti, J. Articles by Tsokos, M.

American Journal of Pathology, Vol 149, 143-151, Copyright © 1996 by American Society for Investigative Pathology

REGULAR ARTICLES

The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein

J Keleti, MM Quezado, MM Abaza, M Raffeld and M Tsokos
Pediatric Tumor Biology-Ultrastructural Pathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

MDM2 gene overexpression has been implicated in the pathogenesis of human neoplasia via inhibition of the p53 tumor-suppressor function. To investigate the potential involvement of the MDM2 oncogene in the pathogenesis of childhood rhabdomyosarcoma (RMS) we studied MDM2 abnormalities in six RMS cell lines in correlation with the p53 status. Three showed overexpression of MDM2 mRNA and protein, one with concomitant MDM2 gene amplification. All three lacked p53 mutation and expressed low levels of p53 mRNA but exhibited elevated p53 proteins. Double immunostaining revealed that the overexpressed MDM2 and p53 proteins were co-localized to the same cell nuclei. Furthermore, the two proteins were physically associated, as shown by co- immunoprecipitation and Western blot analysis. The half-life of the p53 protein was prolonged in the MDM2-expressing RMS cells. The extended half-life wildtype p53 protein and its complex formation with the elevated MDM2 suggest that the underlying mechanism for p53 protein accumulation in these cell lines is p53 stabilization by an overabundant MDM2 protein. The overexpressed MDM2 protein had a short half-life. The three remaining RMS cell lines exhibited low MDM2 mRNA and protein levels and carried p53 mutations. This study suggest that MDM2 overexpression represents an alternative mechanism for p53 inactivation in a subset of childhood RMS without p53 mutations. The results further indicate that the elevated MDM2 protein is responsible for wildtype p53 protein accumulation via stabilization.

This article has been cited by other articles:

				D. M. Langenau, M. D. Keefe, N. Y. Storer, J. R. Guyon, J. L. Kutok, X. Le, W. Goessling, D. S. Neuberg, L. M. Kunkel, and L. I. Zon Effects of RAS on the genesis of embryonal rhabdomyosarcoma Genes & Dev., June 1, 2007; 21(11): 1382 - 1395. [Abstract] [Full Text] [PDF]

				R. Saab, J. L. Bills, A. P. Miceli, C. M. Anderson, J. D. Khoury, D. W. Fry, F. Navid, P. J. Houghton, and S. X. Skapek Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells Mol. Cancer Ther., May 1, 2006; 5(5): 1299 - 1308. [Abstract] [Full Text] [PDF]

				S. Giglio, F. Mancini, F. Gentiletti, G. Sparaco, L. Felicioni, F. Barassi, C. Martella, A. Prodosmo, S. Iacovelli, F. Buttitta, et al. Identification of an Aberrantly Spliced Form of HDMX in Human Tumors: A New Mechanism for HDM2 Stabilization Cancer Res., November 1, 2005; 65(21): 9687 - 9694. [Abstract] [Full Text] [PDF]

				P. P. McKenzie, C. R. McPake, A. A. Ashford, E. F. Vanin, and L. C. Harris MDM2 Does Not Influence p53-mediated Sensitivity to DNA-damaging Drugs Mol. Cancer Ther., October 1, 2002; 1(12): 1097 - 1104. [Abstract] [Full Text] [PDF]

				J. Anderson, A. Ramsay, S. Gould, and K. Pritchard-Jones PAX3-FKHR Induces Morphological Change and Enhances Cellular Proliferation and Invasion in Rhabdomyosarcoma Am. J. Pathol., September 1, 2001; 159(3): 1089 - 1096. [Abstract] [Full Text] [PDF]

				N. Keshelava, J. J. Zuo, P. Chen, S. N. Waidyaratne, M. C. Luna, C. J. Gomer, T. J. Triche, and C. P. Reynolds Loss of p53 Function Confers High-Level Multidrug Resistance in Neuroblastoma Cell Lines Cancer Res., August 1, 2001; 61(16): 6185 - 6193. [Abstract] [Full Text] [PDF]

				T. Adachi, Y. Oda, A. Sakamoto, T. Saito, S. Tamiya, K. Masuda, and M. Tsuneyoshi Immunoreactivity of p53, mdm2, and p21WAFL in Dedifferentiated Liposarcoma: Special Emphasis on the Distinct Immunophenotype of the Well-differentiated Component International Journal of Surgical Pathology, April 1, 2001; 9(2): 99 - 109. [Abstract] [PDF]

				S. Sarkar, K. P. Jülicher, M. S. Burger, V. Della Valle, C.-J. Larsen, T. R. Yeager, T. B. Grossman, R. W. Nickells, C. Protzel, D. F. Jarrard, et al. Different Combinations of Genetic/Epigenetic Alterations Inactivate the p53 and pRb Pathways in Invasive Human Bladder Cancers Cancer Res., July 1, 2000; 60(14): 3862 - 3871. [Abstract] [Full Text]

				D. A. Freedman Regulation of the p53 Protein by the MDM2 Oncoprotein--Thirty-eighth G. H. A. Clowes Memorial Award Lecture Cancer Res., January 1, 1999; 59(1): 1 - 7. [Full Text] [PDF]

				C. Zietz, M. Rossle, C. Haas, A. Sendelhofert, A. Hirschmann, M. Sturzl, and U. Lohrs MDM-2 Oncoprotein Overexpression, p53 Gene Mutation, and VEGF Up-Regulation in Angiosarcomas Am. J. Pathol., November 1, 1998; 153(5): 1425 - 1433. [Abstract] [Full Text] [PDF]

				T. Leveillard and B. Wasylyk The MDM2 C-terminal Region Binds to TAFII250 and Is Required for MDM2 Regulation of the Cyclin A Promoter J. Biol. Chem., December 5, 1997; 272(49): 30651 - 30661. [Abstract] [Full Text] [PDF]